Conduit Pharmaceuticals Stock Performance
| CDTTW Stock | 0.01 0 20.25% |
The firm shows a Beta (market volatility) of 4.38, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Conduit Pharmaceuticals will likely underperform. At this point, Conduit Pharmaceuticals has a negative expected return of -0.65%. Please make sure to confirm Conduit Pharmaceuticals' jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if Conduit Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Conduit Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in March 2026. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors. ...more
| Begin Period Cash Flow | 4.2 M | |
| Total Cashflows From Investing Activities | -43 K | |
| Free Cash Flow | -9.7 M |
Conduit Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1.24 in Conduit Pharmaceuticals on November 2, 2025 and sell it today you would lose (0.61) from holding Conduit Pharmaceuticals or give up 49.19% of portfolio value over 90 days. Conduit Pharmaceuticals is currently producing negative expected returns and takes up 12.234% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Conduit, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Conduit Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Conduit Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.01 | 90 days | 0.01 | about 89.49 |
Based on a normal probability distribution, the odds of Conduit Pharmaceuticals to move above the current price in 90 days from now is about 89.49 (This Conduit Pharmaceuticals probability density function shows the probability of Conduit Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon the stock has the beta coefficient of 4.38 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Conduit Pharmaceuticals will likely underperform. Additionally Conduit Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Conduit Pharmaceuticals Price Density |
| Price |
Predictive Modules for Conduit Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Conduit Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Conduit Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Conduit Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Conduit Pharmaceuticals is not an exception. The market had few large corrections towards the Conduit Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Conduit Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Conduit Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.83 | |
β | Beta against Dow Jones | 4.38 | |
σ | Overall volatility | 0 | |
Ir | Information ratio | -0.06 |
Conduit Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Conduit Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Conduit Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Conduit Pharmaceuticals generated a negative expected return over the last 90 days | |
| Conduit Pharmaceuticals has high historical volatility and very poor performance | |
| Conduit Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Conduit Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 922.22 M. Net Loss for the year was (17.8 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Conduit Pharmaceuticals generates negative cash flow from operations |
Conduit Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Conduit Stock often depends not only on the future outlook of the current and potential Conduit Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Conduit Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 2.1 M | |
| Dividends Paid | 8.2 M | |
| Cash And Short Term Investments | 554 K |
Conduit Pharmaceuticals Fundamentals Growth
Conduit Stock prices reflect investors' perceptions of the future prospects and financial health of Conduit Pharmaceuticals, and Conduit Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Conduit Stock performance.
| Return On Asset | -2.07 | ||||
| Revenue | 922.22 M | ||||
| EBITDA | (15.84 M) | ||||
| Total Debt | 7.46 M | ||||
| Book Value Per Share | 3.35 X | ||||
| Cash Flow From Operations | (9.68 M) | ||||
| Total Asset | 4.19 M | ||||
| Retained Earnings | (29.1 M) | ||||
About Conduit Pharmaceuticals Performance
Evaluating Conduit Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Conduit Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Conduit Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about Conduit Pharmaceuticals performance evaluation
Checking the ongoing alerts about Conduit Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Conduit Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Conduit Pharmaceuticals generated a negative expected return over the last 90 days | |
| Conduit Pharmaceuticals has high historical volatility and very poor performance | |
| Conduit Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Conduit Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 922.22 M. Net Loss for the year was (17.8 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Conduit Pharmaceuticals generates negative cash flow from operations |
- Analyzing Conduit Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Conduit Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Conduit Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Conduit Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Conduit Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Conduit Pharmaceuticals' stock. These opinions can provide insight into Conduit Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Conduit Stock Analysis
When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.